지아이이노베이션

358570KOSDAQ자연과학 및 공학 연구개발업

51.7 / 100

Reference Date: 2026-07-24

Financial Score22.0 / 40

News Sentiment17.7 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 35.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GI Innovation is a biotechnology company specializing in the development of next-generation immune therapies based on fusion proteins, with key drug pipelines including GI-101, GI-102, GI-301, and GI-108. The company utilizes its proprietary GI-SMART™ platform technology to rapidly develop novel bispecific fusion proteins and has achieved growth through technology transfer collaborations with global partners.

Number of Employees

82people

Average Salary

131.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

4.18Industry Average 2.521.0Point

1.7x industry avg (risky)

ROE

-48.28Industry Average -32.093.5Point

1.5x industry avg (good)

Debt Ratio

1.47Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲11921.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -77.1% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 5Neutral 3Negative 0Average Sentiment Score 70.6

Positive
타사 간 혁신 신약 병용요법 급여 초읽기…K바이오도 "관심 집중"
지아이이노베이션 관련 ADC와 면역항암제 병용요법의 급여 신청이 진행되며, 이는 회사의 신약 가치 상승과 시장 관심 증가로 이어질 것으로 기대된다.
Positive
지아이이노베이션, 연내 기술이전 체결 기대감 커진다 [Why 바이오]
지아이이노베이션의 연내 기술이전 계약 기대감 증가로 긍정적인 시장 반응 예상.
Neutral
기술수출 13조에도 잠잠한 K바이오…하반기 이벤트에 쏠린 눈
K바이오 전반의 글로벌 경쟁력 확인이 하반기 반등을 기대하게 하지만, 지아이이노베이션(358570)에 대한 직접적인 영향은 제한적이다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 7,550Won52-week high 20,90052-week low 6,870

1-month return0.0Point

1m -35.80% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-23
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-23
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-13
Neutral투자판단관련주요경영사항(임상시험계획변경승인) (GI108 제1/2a상 임상시험계획 한국식품의약품안전처 변경승인)2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-06